½ÃÀ庸°í¼­
»óǰÄÚµå
1602106

±Ý¿¬ ¹× ´ÏÄÚÆ¾ Á¦°Å Á¦Ç° ½ÃÀå : Á¦Ç°º°, À¯Å뺰 - ¼¼°è ¿¹Ãø(2025-2030³â)

Smoking Cessation & Nicotine De-Addiction Product Market by Product (Drug Therapy, E-Cigarettes, Nicotine Inhalers), Distribution (Drug Store, Hospital Pharmacies, Online Pharmacies) - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 182 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

±Ý¿¬¡¤´ÏÄÚÆ¾ Á¦°Å Á¦Ç° ½ÃÀåÀº 2023³â¿¡ 282¾ï 5,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2024³â¿¡´Â 308¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 9.65%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 538¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

±Ý¿¬ ¹× ´ÏÄÚÆ¾ Á¦°Å Á¦Ç° ½ÃÀåÀÇ ¹üÀ§´Â ´ÏÄÚÆ¾ ´ëü¿ä¹ý(NRT), ºñ´ÏÄÚÆ¾ ¾à¹°, ÀüÀÚ ´ã¹è, ´ÏÄÚÆ¾ ²­, ÆÐÄ¡, ¸¶¸§¸ð²Ã, Çൿ ¿ä¹ý µî ´Ù¾çÇÑ Á¦Ç°À» Æ÷ÇÔÇÕ´Ï´Ù. ÀÌ ½ÃÀåÀº ±Ý¿¬°ú ´ÏÄÚÆ¾ Áßµ¶À» ÁÙÀÌ·Á´Â Èí¿¬ÀÚ¸¦ ´ë»óÀ¸·Î Çϸç, °³ÀÎ »ç¿ëÀÚ, ÀÇ·á ½Ã¼³, ÀçȰ¼¾ÅÍ µî ´Ù¾çÇÑ ¿ëµµ·Î »ç¿ëµË´Ï´Ù. ÀÌ·¯ÇÑ Á¦Ç°ÀÇ Çʿ伺Àº Àü ¼¼°è¿¡¼­ °Ç°­ÇÑ ¶óÀÌÇÁ½ºÅ¸ÀÏÀ» Ãß±¸ÇÏ´Â Ãß¼¼, Èí¿¬°ú °ü·ÃµÈ °Ç°­ À§Çè¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ±Ý¿¬ ¹× ´ã¹è Á¦Ç°¿¡ ´ëÇÑ ¼¼±Ý °­È­¿Í °°Àº Á¤ºÎÀÇ Áö¿ø ³ë·Â¿¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â Á¦Ç° ¼³°èÀÇ ±â¼úÀû Áøº¸, ±Ý¿¬ º¸Á¶Á¦¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, À¯¸®ÇÑ È¯±Þ Á¤Ã¥ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ½ÅÈï ±¹°¡ ½ÃÀå ÁøÃâ È®´ë, µðÁöÅÐ Ç÷§ÆûÀ» Ȱ¿ëÇÑ ¼ÒºñÀÚ È«º¸, ¸ÂÃãÇü ±Ý¿¬ ÇÁ·Î±×·¥À» À§ÇÑ ¸ÂÃãÇü NRT ¹× ½º¸¶Æ®Æù¿ë ¿ëµµ°ú °°Àº Çõ½ÅÀû Á¦Ç° °³¹ß µî ÃֽŠÀáÀçÀû ±âȸµéÀÌ ÀÖ½À´Ï´Ù. ±×·¯³ª ½ÃÀå ¼ºÀå¿¡´Â ¾ö°ÝÇÑ ±ÔÁ¦ ȯ°æ, Á¦³×¸¯ Á¦Ç°°úÀÇ Ä¡¿­ÇÑ °æÀï, ±Ý¿¬ ¼Ö·ç¼ÇÀÇ È¿°ú¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ È¸ÀÇÀûÀÎ ½Ã°¢ µî ¿©·¯ °¡Áö °úÁ¦°¡ ÀÖ½À´Ï´Ù. ½ÇÁúÀûÀÎ ÀÓ»óÀû ±Ù°Å°¡ ÇÊ¿äÇÏ°í ³ôÀº ¾ÈÀü ±âÁØÀ» ÃæÁ·ÇØ¾ß ÇÑ´Ù´Â Á¡µµ ½ÃÀå È®´ë¿¡ °É¸²µ¹·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. º¸´Ù È¿°úÀûÀÌ°í ºÎÀÛ¿ëÀÌ ÀûÀº Á¦Ç°À» ¸¸µé±â À§ÇØ Àü·«ÀûÀ¸·Î ¿¬±¸°³¹ß¿¡ ÅõÀÚÇϰí, °³¹ß ¹× À¯ÅëÀ» À§ÇÑ Àü·«Àû Á¦ÈÞ¸¦ ¸ÎÀ½À¸·Î½á ÀÌ·¯ÇÑ Á¦¾à ¿äÀο¡ ´ëÀÀÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¼ú Çõ½ÅÀÌ ÇÊ¿äÇÑ ºÐ¾ß¿¡´Â ÇöÀç »ç¿ë °¡´ÉÇÑ NRTÀÇ ´ëüǰ Ž»ö, °³ÀÎÈ­µÈ ÀÇ·á Á¢±Ù¹ý °³¹ß, ¼ÒºñÀÚ Âü¿©¿Í È¿´É ÃßÀûÀ» °³¼±Çϱâ À§ÇÑ ±â¼ú°ú °úÇÐÀÇ ÅëÇÕ µîÀÌ ÀÖ½À´Ï´Ù. °æÀïÀû °íÂû¿¡ µû¸£¸é ½ÃÀåÀº Æ÷Æ®Æú¸®¿À¸¦ È®ÀåÇÏ°í ¹ÌÁöÀÇ Àα¸ÃþÀ» °³Ã´Çϱâ À§ÇØ M& A Ȱµ¿À¸·Î Å©°Ô ±â¿ï°í ÀÖÀ¸¸ç, °æÀï·ÂÀ» À¯ÁöÇϱâ À§ÇÑ Àü·«Àû ÀûÀÀ°ú ¹Îø¼ºÀÇ Çʿ伺ÀÌ °­Á¶µÇ°í ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ[2023] 282¾ï 5,000¸¸ ´Þ·¯
¿¹Ãø³â[2024] 308¾ï 9,000¸¸ ´Þ·¯
¿¹Ãø³â[2030] 538¾ï 7,000¸¸ ´Þ·¯
CAGR(%) 9.65%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ±Ý¿¬ ¹× ´ÏÄÚÆ¾ Á¦°Å Á¦Ç° ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

±Ý¿¬ ¹× ´ÏÄÚÆ¾ Á¦°Å Á¦Ç° ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ» ÅëÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¿ªÀû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Èí¿¬À¸·Î ÀÎÇÑ È£Èí±â Áúȯ, Æó¾Ï µî ¼ö¸¹Àº Áúº´ÀÇ À¯º´·ü Áõ°¡
    • ¼¼°è Å»Áßµ¶ Á¦Ç° ½ÃÀå ħÅõ È®´ë
    • ±Ý¿¬ Á¤Ã¥ ÃßÁøÀ» À§ÇÑ Á¤ºÎÀÇ Àû±ØÀûÀÎ ³ë·Â°ú Èí¿¬ÀÌ °Ç°­¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǽÄÀÇ Çâ»ó
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±â¼úÀû °áÇÔ Áõ°¡¿Í ¾ö°ÝÇÑ ½ÂÀÎ ÀýÂ÷·Î ÀÎÇØ Á¦Á¶¾÷ü¿Í ±â¾÷ÀÇ Á¦Ç° ȸ¼ö Áõ°¡
  • ½ÃÀå ±âȸ
    • »õ·Î¿î ´ÏÄÚÆ¾ ´ëü Á¦Ç° ½ÂÀÎ ¹× °³¹ß Áõ°¡
    • ±Ý¿¬º¸Á¶Á¦Ç°¿¡ ´ëÇÑ »çȸÀû, Áö¿ªÀû ÁöÁö¿Í ÇÔ²² ¿Â¶óÀÎ ½ÃÀå¿¡¼­ÀÇ Á¸Àç°¨ÀÌ Å®´Ï´Ù.
  • ½ÃÀå °úÁ¦
    • ±Ý¿¬ º¸Á¶Á¦ÀÇ Áö¼ÓÀû »ç¿ë¿¡ µû¸¥ ºÎÀÛ¿ë°ú ´ã¹è ´ëüǰÀÇ ºÎ»ó

Portre's Five Forces: ±Ý¿¬ ¹× ´ÏÄÚÆ¾ Á¦°Å Á¦Ç° ½ÃÀå Ž»öÀ» À§ÇÑ Àü·« Åø

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ ÅøÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇÏ°í ¾àÁ¡À» º¸¿ÏÇϸç ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇÔÀ¸·Î½á º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ±Ý¿¬ ¹× ´ÏÄÚÆ¾ Á¦°Å Á¦Ç° ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ±Ý¿¬ ¹× ´ÏÄÚÆ¾ Á¦°Å Á¦Ç° ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ±Ý¿¬ ¹× ´ÏÄÚÆ¾ Á¦°Å Á¦Ç° ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

±Ý¿¬ ¹× ´ÏÄÚÆ¾ Á¦°Å Á¦Ç° ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ º¥´õÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¸ÅÃâ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®À» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ±Ý¿¬ ¹× ´ÏÄÚÆ¾ Á¦°Å Á¦Ç° ½ÃÀå¿¡¼­ÀÇ º¥´õ ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ±Ý¿¬ ¹× ´ÏÄÚÆ¾ Á¦°Å Á¦Ç° ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ ÅøÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀº º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ±¸ºÐÇÏ¿© »ç¿ëÀÚ°¡ Àü·«Àû¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù. :

1. ½ÃÀå ħÅõµµ : ¾÷°è ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅ͸¦ Æ÷ÇÔÇÑ ÇöÀç ½ÃÀå ȯ°æ¿¡ ´ëÇÑ »ó¼¼ÇÑ °ËÅä.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸°³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù. :

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÔ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ±Ý¿¬¡¤´ÏÄÚÆ¾ Á¦°Å Á¦Ç° ½ÃÀå : Á¦Ç°º°

  • ¾à¹° ¿ä¹ý
    • Chantix(Varenicline)
    • Zyban(Bupropion)
  • ÀüÀÚ´ã¹è
  • ´ÏÄÚÆ¾ ÈíÀÔ±â
  • ´ÏÄÚÆ¾ ġȯ ¿ä¹ý
    • ´ÏÄÚÆ¾ ²­
    • ´ÏÄÚÆ¾ ·ÎÁ¨Áö
    • ´ÏÄÚÆ¾ ½ºÇÁ·¹ÀÌ
    • ´ÏÄÚÆ¾ °æÇÇ ÆÐÄ¡
  • ´ÏÄÚÆ¾ ¼³ÇÏÁ¤

Á¦7Àå ±Ý¿¬¡¤´ÏÄÚÆ¾ Á¦°Å Á¦Ç° ½ÃÀå : À¯Å뺰

  • µå·¯±×½ºÅä¾î
  • º´¿ø ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹
  • ¼Ò¸Å ¾à±¹

Á¦8Àå ¾Æ¸Þ¸®Ä«ÀÇ ±Ý¿¬¡¤´ÏÄÚÆ¾ Á¦°Å Á¦Ç° ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ý¿¬¡¤´ÏÄÚÆ¾ Á¦°Å Á¦Ç° ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦10Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ±Ý¿¬¡¤´ÏÄÚÆ¾ Á¦°Å Á¦Ç° ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®
  • ¿µ±¹

Á¦11Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®

±â¾÷ ¸®½ºÆ®

  • 22nd Century Group, Inc.
  • Alkalon A/S
  • Axsome Therapeutics, Inc.
  • British American Tobacco PLC
  • Cipla Ltd.
  • Ditch Labs
  • Dr. Reddy's Laboratories Limited
  • Enorama Pharma AB
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Imperial Tobacco Company of India Limited
  • Itaconix
  • Japan Tobacco Inc.
  • Johnson & Johnson
  • JUUL Labs, Inc.
  • Novartis International AG
  • Perrigo Company PLC
  • Pfizer Inc.
  • Philip Morris International Inc.
  • Pierre Fabre S.A.
  • Rusan Pharma Ltd.
  • Samyang Holdings Corporation
  • Sparsha Pharma International Pvt. Ltd.
  • Strides Pharma Science Limited
KSA 24.12.10

The Smoking Cessation & Nicotine De-Addiction Product Market was valued at USD 28.25 billion in 2023, expected to reach USD 30.89 billion in 2024, and is projected to grow at a CAGR of 9.65%, to USD 53.87 billion by 2030.

The scope of the Smoking Cessation & Nicotine De-Addiction Product market includes a diverse range of products such as nicotine replacement therapies (NRT), non-nicotine medications, e-cigarettes, nicotine gums, patches, lozenges, and behavioral therapies. This market targets smokers seeking to quit and reduce nicotine dependency, with applications spanning across individual users, healthcare facilities, and rehabilitation centers. The necessity for these products is driven by the global push toward healthier lifestyles, increasing awareness of smoking-related health hazards, and supportive government initiatives, such as smoking bans and higher taxes on tobacco products. Key influencing growth factors include technological advancements in product design, increasing awareness about smoking cessation aids, and favorable reimbursement policies. Latest potential opportunities lie in expanding market presence in emerging economies, leveraging digital platforms for consumer outreach, and developing innovative products like tailor-made NRTs and smartphone applications for personalized cessation programs. However, market growth faces challenges such as stringent regulatory environments, high competition from generic products, and possible consumer skepticism toward the efficacy of de-addiction solutions. The need for substantial clinical backing and the requirement to meet high safety standards could also hinder swift market expansion. Limiting factors can be countered by strategically investing in R&D to create more effective and less side-effect-prone products and by forming strategic alliances for development and distribution. Areas ripe for innovation include exploring alternatives to currently available NRTs, developing personalized medicine approaches, and integrating technology and science for better consumer engagement and efficacy tracking. Insightfully, the market is evolving with a significant tilt toward merger and acquisition activities, to expand portfolios and tap uncharted demographics, highlighting the need for strategic adaptation and agility to remain competitive.

KEY MARKET STATISTICS
Base Year [2023] USD 28.25 billion
Estimated Year [2024] USD 30.89 billion
Forecast Year [2030] USD 53.87 billion
CAGR (%) 9.65%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Smoking Cessation & Nicotine De-Addiction Product Market

The Smoking Cessation & Nicotine De-Addiction Product Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing Prevalence of Numerous Diseases due to Smoking Such as Respiratory Disorders and Lung Cancer
    • Expanding Market Penetration of De-Addiction Products Globally
    • Favorable Government Initiatives to Promote Anti-Smoking Policy and Raising Awareness of the Health Impact due to Smoking
  • Market Restraints
    • Product Recalls by the Manufacturer and Companies owing to increasing Technical Faults and Stringent Approval Process
  • Market Opportunities
    • Increasing Approvals and Development of New Nicotine Replacement Products
    • Significant Online Market Presence Coupled with Social and Communal Support for Smoking Cessation Products
  • Market Challenges
    • Side Effects Associated with the Continued Usage of De-Addiction Products Coupled with Rising of Alternatives to Tobacco

Porter's Five Forces: A Strategic Tool for Navigating the Smoking Cessation & Nicotine De-Addiction Product Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Smoking Cessation & Nicotine De-Addiction Product Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Smoking Cessation & Nicotine De-Addiction Product Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Smoking Cessation & Nicotine De-Addiction Product Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Smoking Cessation & Nicotine De-Addiction Product Market

A detailed market share analysis in the Smoking Cessation & Nicotine De-Addiction Product Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Smoking Cessation & Nicotine De-Addiction Product Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Smoking Cessation & Nicotine De-Addiction Product Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Smoking Cessation & Nicotine De-Addiction Product Market, highlighting leading vendors and their innovative profiles. These include 22nd Century Group, Inc., Alkalon A/S, Axsome Therapeutics, Inc., British American Tobacco PLC, Cipla Ltd., Ditch Labs, Dr. Reddy's Laboratories Limited, Enorama Pharma AB, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Imperial Tobacco Company of India Limited, Itaconix, Japan Tobacco Inc., Johnson & Johnson, JUUL Labs, Inc., Novartis International AG, Perrigo Company PLC, Pfizer Inc., Philip Morris International Inc., Pierre Fabre S.A., Rusan Pharma Ltd., Samyang Holdings Corporation, Sparsha Pharma International Pvt. Ltd., and Strides Pharma Science Limited.

Market Segmentation & Coverage

This research report categorizes the Smoking Cessation & Nicotine De-Addiction Product Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Drug Therapy, E-Cigarettes, Nicotine Inhalers, Nicotine Replacement Therapies, and Nicotine Sublingual Tablets. The Drug Therapy is further studied across Chantix (Varenicline) and Zyban (Bupropion). The Nicotine Replacement Therapies is further studied across Nicotine Gums, Nicotine Lozenges, Nicotine Sprays, and Nicotine Transdermal Patches.
  • Based on Distribution, market is studied across Drug Store, Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing Prevalence of Numerous Diseases due to Smoking Such as Respiratory Disorders and Lung Cancer
      • 5.1.1.2. Expanding Market Penetration of De-Addiction Products Globally
      • 5.1.1.3. Favorable Government Initiatives to Promote Anti-Smoking Policy and Raising Awareness of the Health Impact due to Smoking
    • 5.1.2. Restraints
      • 5.1.2.1. Product Recalls by the Manufacturer and Companies owing to increasing Technical Faults and Stringent Approval Process
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing Approvals and Development of New Nicotine Replacement Products
      • 5.1.3.2. Significant Online Market Presence Coupled with Social and Communal Support for Smoking Cessation Products
    • 5.1.4. Challenges
      • 5.1.4.1. Side Effects Associated with the Continued Usage of De-Addiction Products Coupled with Rising of Alternatives to Tobacco
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Rising adoption of E-cigarettes for smoking cessation
    • 5.2.2. Distribution: Customer inclination towards online pharmacies for convenience and discretion
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Smoking Cessation & Nicotine De-Addiction Product Market, by Product

  • 6.1. Introduction
  • 6.2. Drug Therapy
    • 6.2.1. Chantix (Varenicline)
    • 6.2.2. Zyban (Bupropion)
  • 6.3. E-Cigarettes
  • 6.4. Nicotine Inhalers
  • 6.5. Nicotine Replacement Therapies
    • 6.5.1. Nicotine Gums
    • 6.5.2. Nicotine Lozenges
    • 6.5.3. Nicotine Sprays
    • 6.5.4. Nicotine Transdermal Patches
  • 6.6. Nicotine Sublingual Tablets

7. Smoking Cessation & Nicotine De-Addiction Product Market, by Distribution

  • 7.1. Introduction
  • 7.2. Drug Store
  • 7.3. Hospital Pharmacies
  • 7.4. Online Pharmacies
  • 7.5. Retail Pharmacies

8. Americas Smoking Cessation & Nicotine De-Addiction Product Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Smoking Cessation & Nicotine De-Addiction Product Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Smoking Cessation & Nicotine De-Addiction Product Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. BC Cancer Launches Nicotine Replacement Therapy Pilot Program in Prince George
    • 11.3.2. Imperial Tobacco Canada Is Excited To Launch A Smoking Cessation Product
    • 11.3.3. NCDHHS Launches New QuitlineNC Services to Make Stopping Tobacco Use and Vaping More Accessible

Companies Mentioned

  • 1. 22nd Century Group, Inc.
  • 2. Alkalon A/S
  • 3. Axsome Therapeutics, Inc.
  • 4. British American Tobacco PLC
  • 5. Cipla Ltd.
  • 6. Ditch Labs
  • 7. Dr. Reddy's Laboratories Limited
  • 8. Enorama Pharma AB
  • 9. GlaxoSmithKline PLC
  • 10. Glenmark Pharmaceuticals Limited
  • 11. Imperial Tobacco Company of India Limited
  • 12. Itaconix
  • 13. Japan Tobacco Inc.
  • 14. Johnson & Johnson
  • 15. JUUL Labs, Inc.
  • 16. Novartis International AG
  • 17. Perrigo Company PLC
  • 18. Pfizer Inc.
  • 19. Philip Morris International Inc.
  • 20. Pierre Fabre S.A.
  • 21. Rusan Pharma Ltd.
  • 22. Samyang Holdings Corporation
  • 23. Sparsha Pharma International Pvt. Ltd.
  • 24. Strides Pharma Science Limited
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦